title: Histochemical detection of expression of binding sites for labelled hyaluronic acid and carrier-immobilized synthetic (histo-blood group trisaccharides) or biochemically purified (ganglioside GM1) glycoligands in nasal polyps and other human lesions including neoplasms.
abstract: This study is intended to demonstrate the versatility and feasibility of custom-made oligosaccharide-exposing neoglycoconjugates including histo-blood group epitopes in various human lesions, including nasal polyps. The binding of the biotinylated probes was determined on formalin-fixed paraffin-embedded sections from archive materials. The general aspects of our results may be interpreted as follows: the neoglycoconjugates used here can readily detect differences in the ability of cells to bind glycan residues in tissue sections, thereby enabling the extent of the binding capacity of various types of human lesions to be compared. Furthermore, the reactivity to glycan may reflect characteristics of the cells and their environment. The investigation into pathological disorders with respect to the binding capacity of these carrier-immobilized mono- or oligosaccharide structures derived from custom-made synthesis or biochemical purification is based on the prospect of translating progress in this field into the establishment of potentially beneficial procedures for medical diagnosis and pathological classification.
authors.affiliation: E.N.T. Department, Erasmus University Hospital Brussels, Université Libre de Bruxelles, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Hassid
authors.forename: I
authors.initials: I
authors.lastname: Salmon
authors.forename: N V
authors.initials: NV
authors.lastname: Bovin
authors.forename: R
authors.initials: R
authors.lastname: Kiss
authors.forename: H J
authors.initials: HJ
authors.lastname: Gabius
authors.forename: A
authors.initials: A
authors.lastname: Danguy
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D001665:Binding Sites; D001789:Blood Group Antigens / Q000032:analysis / Q000737:chemistry*; D001932:Brain Neoplasms / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000473:pathology; D003110:Colonic Neoplasms / Q000473:pathology; D005240:Feasibility Studies; D005260:Female; D018226:Fibroadenoma / Q000473:pathology; D005677:G(M1) Ganglioside; D005909:Glioblastoma / Q000473:pathology; D006001:Glycoconjugates / Q000032:analysis*; D006651:Histocytochemistry; D006801:Humans; D006820:Hyaluronic Acid; D008297:Male; D008545:Melanoma / Q000473:pathology; D009298:Nasal Polyps / Q000473:pathology*; D009369:Neoplasms / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology; D014312:Trisaccharides; D001749:Urinary Bladder Neoplasms / Q000473:pathology
chemical_list: D001789:Blood Group Antigens; D006001:Glycoconjugates; D014312:Trisaccharides; D005677:G(M1) Ganglioside; D006820:Hyaluronic Acid